New global registry tracks safety of common blood thinners in APS patients
NCT ID NCT04262492
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is creating a global registry of 500 adults with antiphospholipid syndrome (APS) who are taking direct oral anticoagulants (DOACs) like rivaroxaban or apixaban. Researchers will track rates of recurrent blood clots and bleeding over at least 6 months. The goal is to gather real-world safety information for this specific patient group.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Direct oral anticoagulants (rivaroxaban, dabigatran, apixaban, edoxaban)
What this could lead to
If successful, this registry could provide clearer safety data on using DOACs in low-risk APS patients, potentially guiding future treatment decisions.
What could go wrong
This is an observational registry, not a controlled trial, so it cannot prove cause and effect. Results may be limited by patient selection and real-world variability.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANTIPHOSPHOLIPID SYNDROME are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Stéphane Zuily
RECRUITINGNancy, 54500, France
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact